Garcia‐Burguillo 1996.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 60 adults (macrolide n = 30, placebo n = 30) Age in years (mean ± SD): macrolide: 28.3 ± 5.9, placebo: 27.4 ± 6 Setting: secondary care
Interventions	Indication: preterm rupture of the amniotic membranes Type of macrolide: erythromycin ethyl succinate Route: per oral Dose per day: 2000 mg Duration of treatment: 8 days (mean duration of treatment in erythromycin group) Total treatment dose: 16,000 mg
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: no Adverse events ascertainment: unclear Adverse events: not reported Antimicrobial resistance: not reported Death: reported for babies of treated mothers
Funding sources	None reported.
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation
Allocation concealment (selection bias)	Unclear risk	Allocation not described.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Unclear blinding as placebo not described
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Only reported on death in babies, which is an objective outcome not influenced by blinding or not
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (reporting bias)	High risk	Adverse events not stated as an outcome, unclear ascertainment, adverse events not reported (only death in babies).
Other bias	Low risk	None were identified.